


AMENDMENTS TO THE CLAIMS

1. (CURRENTLY AMENDED) A compound of Formula I



or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof,
wherein

R¹ is selected from the group consisting of an optionally substituted heterocyclyl, and
optionally substituted (heterocyclyl)C₁₋₆alkyl;

R² and R³ are independently selected from the group consisting of hydrogen, C₁₋₆alkyl
and halogen or such that R² together with R³ forms a 3-, 4-, 5-, 6-, or 7-membered ring system
with the atoms of the piperidine ring;

m is 1;

n is selected from the group consisting of 1, 2, and 3;

Ar¹ is an aryl or heteroaryl optionally substituted with a substituent selected from the
group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, carboxyl, amino, hydroxy, thiol, nitro, cyano,
guanidino, carbamido and halogen;

W is selected from the group consisting of oxygen and sulfur;

X is selected from the group consisting of optionally substituted methylene, optionally
substituted ethylene, optionally substituted propylene, optionally substituted vinylene, and
CH₂N(R^N), wherein R^N is selected from hydrogen and C₁₋₆alkyl; and

Ar² is an optionally substituted aryl or heteroaryl.

2. (CURRENTLY AMENDED) The compound of claim 1, wherein said
heterocyclyl or said (heterocyclyl)C₁₋₆alkyl is optionally substituted with one or more groups
selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, alkyl, and amino.

3. (ORIGINAL) The compound of claim 1, wherein said heterocycll is selected from the group conssiting of tetrahydrothiopyran, 4*H*-pyran, tetrahydropyran, piperidine, 1,3-dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1,3-oxathiane, 1,4-oxathiin, 1,4-oxathiane, tetrahydro-1,4-thiazine, 2*H*-1,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, morpholine, trioxane, hexahydro-1,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrrolidine, pyrrolidone, pyrrolidone, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,3-dioxole, 1,3-dioxolane, 1,3-dithiole, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, and 1,3-oxathiolane.

4. (ORIGINAL) The compound of claim 3, wherein said heterocycll is selected from the group consisting of 1,3-dioxane, 1,3-dioxolane, and tetrahydropyran.

5. (CANCELLED)

6. (CANCELLED)

7. (ORIGINAL) The compound of claim 1, wherein R² and R³ are hydrogen.

8. (CANCELLED)

9. (ORIGINAL) The compound of claim 1, wherein n is 1.

10. (ORIGINAL) The compound of claim 1, wherein W is oxygen.

11. (ORIGINAL) The compound of claim 1, wherein Ar¹ is an optionally substituted aryl.

12. (ORIGINAL) The compound of claim 1, wherein Ar¹ is 4-substituted aryl.

13. (ORIGINAL) The compound of claim 1, wherein Ar¹ is selected from the group consisting of alkyl-substituted phenyl, alkoxy-substituted phenyl, halogen-substituted phenyl, hydroxy-substituted phenyl and amino-substituted phenyl.

14. (PREVIOUSLY AMENDED) The compound of claim 13, wherein said alkyl is selected from the group consisting of methyl, ethyl, propyl, n-butyl, sec-butyl and tert-butyl, and said alkoxy is selected from the group consisting of methoxy, ethoxy, propoxy, n-butoxy, sec-butoxy, and tert-butoxy.

15. (CURRENTLY AMENDED) The compound of claim 1213, wherein Ar¹ is halogen-substituted phenyl.

16. (CURRENTLY AMENDED) The compound of claim 1415, wherein said halogen is fluoro.

17. (ORIGINAL) The compound of claim 1, wherein X is selected from the group consisting of optionally substituted methylene, optionally substituted ethylene, and $\text{CH}_2\text{N}(\text{R}^N)$.

18. (CURRENTLY AMENDED) The compound of claim 1617, wherein X is an optionally substituted methylene.

19. (ORIGINAL) The compound of claim 17, wherein X is $\text{CH}_2\text{N}(\text{R}^N)$.

20. (ORIGINAL) The compound of claim 1, wherein Ar^2 is an optionally substituted aryl.

21. (ORIGINAL) The compound of claim 1, wherein Ar^2 is 4-substituted aryl.

22. (ORIGINAL) The compound of claim 20, wherein said substituent on Ar^2 is selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, amino, alkylamino, heteroaryl, and heterocycl.

23. (ORIGINAL) The compound of claim 20, wherein said substituent on Ar^2 is selected from the group consisting of chloro, fluoro, hydroxy, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, trifluoromethoxy, N-morpholinyl, N-pyrrolidinyl, N-pyrazolyl, N-triazolyl and 2-oxopyrrolidinyl.

24. (CURRENTLY AMENDED) A compound selected from the group consisting of

$N-(1-[2-(1,3-Dioxolan-2-yl)ethyl]piperidin-4-yl)-N-(4-fluorobenzyl)-N^-(4-isobutoxybenzyl)carbamide$, hydrochloride;

$N-(1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl)-N-(4-fluorobenzyl)-2-[4-(2-hydroxy-2-methylpropanoyl)phenyl]acetamide$, tartrate;

$N-(4-Fluorobenzyl)-N^-(piperidin-4-yl)-2-(4-isobutoxyphenyl)acetamide$;

$N-(1-[3-(2,5-Dimethylpiperidin-1-yl)propyl]piperidin-4-yl)-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide$, dihydrochloride;

$1-[3-(4-(4-Fluorobenzyl)-[2-(4-isobutoxyphenyl)acetyl]amino)piperidin-1-yl]propyl)piperidine-4-carboxylic acid methyl ester$, dihydrochloride;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[2-(1-methylpyrrolidin-2-yl)ethyl]piperidin-4-yl]acetamide, dioxalate;

~~N-[1-[3-(2,6-Dimethylmorpholin-4-yl)propyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, dioxalate;~~

N-(4-Fluorobenzyl)-N-[1-[3-(3-hydroxypiperidin-1-yl)propyl]piperidin-4-yl]-2-(4-isobutoxyphenyl)acetamide, dioxalate;

~~N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[3-(2-methylpiperidin-1-yl)propyl]piperidin-4-yl]acetamide, dioxalate;~~

~~N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-(3-pyrrolidin-1-yl-propyl)piperidin-4-yl]acetamide, dioxalate;~~

~~N-[1-[3-(2,5-Dimethylpyrrolidin-1-yl)propyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, dioxalate;~~

N-(4-Fluorobenzyl)-N-[1-[3-(3-hydroxymethylpiperidin-1-yl)propyl]piperidin-4-yl]-2-(4-isobutoxyphenyl)acetamide, dioxalate;

~~N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[3-(4-(S)-isopropyl-2-exo-oxazolidin-3-yl)propyl]piperidin-4-yl]acetamide, oxalate;~~

~~N-[2-(4-Fluorophenyl)ethyl]-2-(4-isobutoxyphenyl)-N-[1-[3-(4-(S)-isopropyl-2-exo-oxazolidin-3-yl)propyl]piperidin-4-yl]acetamide, oxalate;~~

~~N-[2-(4-Fluorophenyl)ethyl]-N-[1-[3-(1-(S)-isopropyl-2-exo-oxazolidin-3-yl)propyl]piperidin-4-yl]-2-(4-propoxyphenyl)acetamide, oxalate;~~

~~N-(4-Fluorobenzyl)-N-[1-[3-(4-(S)-isopropyl-2-exo-oxazolidin-3-yl)propyl]piperidin-4-yl]-2-(4-propoxyphenyl)acetamide, oxalate;~~

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, oxalate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-[2-(4-fluorophenyl)ethyl]-2-(4-isobutoxyphenyl)acetamide, oxalate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-[2-(4-fluorophenyl)ethyl]-2-(4-propoxyphenyl)acetamide, oxalate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-propoxyphenyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-Nⁿ(4-isobutoxybenzyl)carbamide, tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-fluorophenyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-p-tolyacetamide, tartrate;

2-Benzofuran-5-yl-N-[1-[2-(1,3-dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)acetamide, tartrate;

2-(2,3-Dihydrobenzofuran-5-yl)-N-[1-[2-(1,3-dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)acetamide, tartrate;

N-[1-[2-(2,2-Dimethyl-1,3-dioxolan-4-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-4-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-4-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-trifluoromethylphenyl)acetamide, tartrate;

2-(4-Cyanophenyl)-N-[1-[2-(1,3-dioxan-4-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)acetamide, tartrate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[2-(2-oxo-imidazolidin-1-yl)ethyl]piperidin-4-yl]acetamide, hydrochloride;

2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-[1-[2-(2-oxo-imidazolidin-1-yl)ethyl]piperidin-4-yl]acetamide, hydrochloride;

N-(4-Fluorobenzyl)-2-(4-isopropoxyphenyl)-N-[1-[2-(2-oxo-imidazolidin-1-yl)ethyl]piperidin-4-yl]acetamide, hydrochloride;

N-(4-Fluorobenzyl)-2-(4-isopropoxyphenyl)-N-[1-[3-(3-methyl-2-oxo-2,3-dihydrobenzoimidazol-1-yl)propyl]piperidin-4-yl]acetamide, hydrochloride;

N-[1-[2-(2,4-Dioxa-1,4-dihydro-2H-quinazolin-3-yl)ethyl]piperidin-4-yl]-2-(4-methoxyphenyl)-N-(4-methylbenzyl)acetamide, hydrochloride;

2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-[1-[3-(2-oxo-2,3-dihydrobenzoimidazol-1-yl)propyl]piperidin-4-yl]acetamide, hydrochloride;

N-(4-Fluorobenzyl)-2-(4-isopropoxyphenyl)-N-[1-[4-(2-oxo-2,3-dihydrobenzoimidazol-1-yl)butyl]piperidin-4-yl]acetamide, hydrochloride;

N-[1-[2-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isopropoxyphenyl)acetamide, hydrochloride;

N-[1-[2-(1,3-Dioxolan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-N'-(4-isopropoxybenzyl)carbamide, oxalate;

N-[1-[2-(1,3-Dioxolan-2-yl)ethyl]piperidin-4-yl]-N-(4-methoxyphenyl)-N-(4-methylbenzyl)acetamide, hydrochloride;

N-[1-[2-(1,3-Dioxolan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, hydrochloride;

N-[1-[2-(1,3-Dioxolan-2-yl)ethyl]piperidin-4-yl]-N-(4-methylbenzyl)-2-(4-isopropoxyphenyl)acetamide, hydrochloride;

N-[1-[2-(1,3-Dioxolan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isopropoxyphenyl)acetamide, tartrate;

N-(4-Fluorobenzyl)-N'-(4-isopropoxybenzyl)-N-[1-[2-((S)-4-methyl-1,3-dioxolan-2-yl)ethyl]piperidin-4-yl]earbamide, oxalate;

N-(4-Fluorobenzyl)-N'-(4-isopropoxybenzyl)-N-[1-(3-morpholin-4-yl-propyl)piperidin-4-yl]earbamide, oxalate;

2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(2-morpholin-4-yl-ethyl)piperidin-4-yl]acetamide, dihydrochloride;

2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(3-morpholin-4-yl-propyl)piperidin-4-yl]acetamide, dihydrochloride;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-(3-morpholin-4-yl-propyl)piperidin-4-yl]acetamide, dihydrochloride;

N-(4-Fluorobenzyl)-2-(4-isopropoxyphenyl)-N-[1-(3-morpholin-4-yl-propyl)piperidin-4-yl]acetamide, dihydrochloride;

N-(4-Fluorobenzyl)-N'-(4-isopropoxybenzyl)-N-[1-(3-piperidin-1-yl-propyl)piperidin-4-yl]earbamide, oxalate;

N-(4-Fluorobenzyl)-N'-(4-isopropoxybenzyl)-N-[1-(3-((S)-4-isopropyl-2-oxazolidinon-1-yl-propyl)piperidin-4-yl)earbamide, tartrate;

N-(4-Fluorobenzyl)-N'-(4-isopropoxybenzyl)-N-[1-[2-(2,5,5-trimethyl-1,3-dioxan-2-yl)ethyl]piperidin-4-yl]carbamide, oxalate;

N-[1-[3-(1,3-Dioxolan-2-yl)propyl]piperidin-4-yl]-N-(4-fluorobenzyl)-N'-(4-isopropoxybenzyl)carbamide, oxalate;

N-[1-(2,2-Dimethyl-1,3-dioxan-5-yl)piperidin-4-yl]-N-(4-fluorobenzyl)-N'-(4-isopropoxybenzyl)carbamide, oxalate;

N-(4-Fluorobenzyl)-N'-(4-isopropoxybenzyl)-N-[{2-(1-methylpyrrolidin-2-yl)ethyl}piperidin-4-yl]carbamide, oxalate;

N-[1-(2,2-Dimethyl-1,3-dioxan-5-yl)piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, oxalate;

N-[1-(1,3-Dioxan-5-yl)-piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, tartrate;

N-[1-(2,2-Dimethyl-1,3-dioxan-5-yl)piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-fluorophenyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-4-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-fluorophenyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-4-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-trifluoromethoxyphenyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-4-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-propoxymethoxyphenyl)acetamide, tartrate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-(tetrahydropyran-4-yl)piperidin-4-yl]acetamide, tartrate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-(tetrahydropyran-4-ylmethyl)piperidin-4-yl]acetamide, tartrate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[2-(tetrahydropyran-4-yl)ethyl]piperidin-4-yl]acetamide, tartrate;

N-(4-Fluorobenzyl)-2-(4-fluorophenyl)-N-[1-(tetrahydropyran-4-yl)piperidin-4-yl]acetamide, tartrate;

N-[1-((S)-3,5-Dihydroxypentyl)piperidine-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, tartrate;

N-[1-[2-((4S)-1,3-Dioxane-4-yl)ethyl]piperidine-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, tartrate;

N-[1-[2-(1,3-dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-hydroxyphenyl)-acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-methoxyphenyl) acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isopropylphenyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-trifluoromethoxyphenyl)acetamide, tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-ethoxyphenyl)-acetamide, oxalate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isopropoxyphenyl)acetamide, oxalate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-phenylacetamide, oxalate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-[4-(2-fluoroethoxy)phenyl]acetamide, oxalate;

N-[1-[2-(5,5-Dimethyl-1,3dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[2-((R)-4-methyl-1,3-dioxan-2-yl)ethyl]piperidin-4-yl]acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[2-((S)-4-methyl-1,3-dioxolan-2-yl)ethyl]piperidin-4-yl]acetamide, oxalate;

N-[1-[2-(4,6-Dimethyl-1,3-dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, oxalate;

N-(4-Fluorobenzyl)-N-[1-[2-((S)-4-methyl-1,3-dioxolan-2-yl)ethyl]piperidin-4-yl]-2-(4-trifluoromethoxyphenyl)acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isopropylphenyl)-N-[1-[2-((S)-4-methyl-1,3-dioxolan-2-yl)ethyl]piperidin-4-yl]acetamide, oxalate;

N-(4-Fluorobenzyl)-N-[1-[2-((R)-4-methyl-1,3-dioxolan-2-yl)ethyl]piperidin-4-yl]-2-(4-trifluoromethoxyphenyl)acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[2-(2,5,5-trimethyl-1,3-dioxolan-2-yl)ethyl]piperidin-4-yl]acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]piperidin-4-yl]acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[3-(1,3-dioxolan-2-yl)propyl]piperidin-4-yl]acetamide, tartrate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-(3-piperidin-1-yl-propyl)piperidin-4-yl]acetamide, dihydrochloride;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[2-(tetrahydropyran-2-yloxy)ethyl]piperidin-4-yl]acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[3-(2-oxo-piperidin-1-yl)propyl]piperidin-4-yl]acetamide;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[3-(2-oxo-pyrrolidin-1-yl)propyl]piperidin-4-yl]acetamide, hydrochloride;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[3-((R)-4-isopropyl-2-oxo-oxazolidin-3-yl)propyl]piperidin-4-yl]acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[3-(2-oxo-oxazolidin-3-yl)propyl]piperidin-4-yl]acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[3-((S)-4-methyl-2-oxo-oxazolidin-3-yl)propyl]piperidin-4-yl]acetamide, tartrate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[3-((S)-4-ethyl-2-oxo-oxazolidin-3-yl)propyl]piperidin-4-yl]acetamide, oxalate;

N-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-N-[1-[2-(1,3-oxethiolan-2-yl)ethyl]piperidin-4-yl]acetamide, L-tartrate;

2-(4-Bromophenyl)-N-[1-[2-(1,3-dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutylamino-phenyl)acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-propylamino-phenyl)acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-(1-nitropropyl)-phenyl)acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-[4-(2-oxopyrrolidin-1-yl)phenyl]acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutylsulfanyl-phenyl)acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-iodophenyl)acetamide, L-tartrate;

2-(4-Aacetophenyl)-N-[1-[2-(1,3-dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-acetamide, L-tartrate;

2-[4-(1-Hydroxyiminoethyl)phenyl]-N-[1-[2-(1,3-dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-morpholin-4-yl-phenyl)acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-pyrazol-1-ylphenyl)acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-2-yl)-1-methylethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, L-tartrate;

N-[1-[2-(1,3-Dioxan-4-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-(4-pyrazol-1-ylphenyl)acetamide, L-tartrate;

N-[1-[2-((4R)-1,3-Dioxane-4-yl)ethyl]piperidine-4-yl]-N-(4-fluorobenzyl)-2-(4-isobutoxyphenyl)acetamide, tartrate; and

N-[1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl]-N-(4-fluorobenzyl)-2-[4-(1,2,4-triazol-4-yl)phenyl]acetamide, L-tartrate.

25. (CURRENTLY AMENDED) A method of inhibiting an activity of a 5HT2A receptor in vitro comprising contacting the 5HT2A receptor with a compound of claim 1.

26. (CURRENTLY AMENDED) A method of inhibiting an activation of a 5HT2A receptor in vitro comprising contacting the 5HT2A receptor with a compound of claim 1.
27. (CURRENTLY AMENDED) A method of treating ~~a disease condition associated with a 5HT2A receptor psychosis~~ comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1
- 28.-35. (CANCELLED)
36. (NEW) The method of claim 25, wherein the 5HT2A receptor is mutated or modified.
37. (NEW) The method of claim 25, wherein the activity is signaling activity.
38. (NEW) The method of claim 25, wherein the activity is constitutive.
39. (NEW) The method of claim 25 wherein the activity is associated with serotonin receptor activation.
40. (NEW) The method of claim 26, wherein the activation is by an agonistic agent.
41. (NEW) The method of claim 40, wherein the agonistic agent is exogenous.
42. (NEW) The method of claim 40, wherein the agonistic agent is endogenous.
43. (NEW) The method of claim 26, wherein the activation is constitutive.
44. (NEW) The method of claim 26, wherein the 5HT2A receptor is mutated or modified.